Beyond Cydectin’s mission partnership with Wounded Warrior Project, Boehringer Ingelheim Vetmedica, Inc. ran a special program that would donate $1 for every liter of Cydectin Pour-On sold from March 1 to May 31, 2011. The Spring Buck-a-Liter program garnered an overwhelming response with a total of 199,780 liters of Cydectin Pour-on sold, which yielded a donation of $199,780 to Wounded Warrior Project.
“Globally, Boehringer Ingelheim is committed to social responsibility; and our support of Wounded Warrior Project is just one example of this. We are so honored to support this worthy cause and hope this token of support through the Buck-a-Liter program can make a difference in the lives of returning veterans,” says Colin Meyers, Executive Director, U.S. Cattle Business & Process Excellence with Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc. through its Cydectin Pour-On product partnered with Wounded Warrior Project in 2010 to create the Cydectin Honor Our Troops program. This unique collaboration shows returning veterans that America's beef and dairy producers are grateful for their sacrifice and service. For more information on the Cydectin Honor Our Troops program, visit www.cydectinhonorstroops.com.
“Wounded Warrior Project is extremely grateful for the amazing support Boehringer Ingelheim Vetmedica, Inc., continues to provide to our organization and the wounded heroes we proudly serve,” says Jonathan Sullivan, Executive Vice President of Development for Wounded Warrior Project. “This unique partnership and campaign will have a positive impact on our nation’s wounded warriors.”
“We were overwhelmed with the response we received during our Spring Buck-a-Liter program,” says Mike Randolph, Senior Brand Manager for Cydectin. “Participating producers should know that through their purchase of Cydectin Pour-On, they are helping welcome countless wounded soldiers home, and we are so grateful to these producers for joining us to support this great cause.”
Wounded Warrior Project (WWP) is a national, nonprofit organization whose mission is to honor and empower wounded warriors. WWP works to raise awareness, and enlists the public’s help in meeting the needs of injured service members. Over 45,000 of our nation’s armed forces have been physically wounded during the current military conflicts. Hundreds of thousands more are estimated to be recovering from invisible wounds of war, including post-traumatic stress disorder, major depression, and traumatic brain injury. WWP assists wounded warriors and their families through a holistic approach to their recovery. Whether through caregiver retreats, combat stress programs, career and education services, or adaptive sporting opportunities, WWP empowers warriors with the tools essential to not just survive their injuries but to thrive and achieve personal and professional success. To get involved and learn more, visit woundedwarriorproject.org.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim — and its employees — carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24 percent of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com.